Legg Mason Asset Management Japan Co. Ltd. cut its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 4.7% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 4,100 shares of the company’s stock after selling 200 shares during the quarter. Legg Mason Asset Management Japan Co. Ltd.’s holdings in IDEXX Laboratories were worth $763,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Vanguard Group Inc. raised its position in shares of IDEXX Laboratories by 0.3% in the 3rd quarter. Vanguard Group Inc. now owns 8,918,451 shares of the company’s stock worth $2,226,581,000 after acquiring an additional 23,970 shares in the last quarter. Vanguard Group Inc increased its position in IDEXX Laboratories by 0.3% in the 3rd quarter. Vanguard Group Inc now owns 8,918,451 shares of the company’s stock valued at $2,226,581,000 after buying an additional 23,970 shares in the last quarter. BlackRock Inc. increased its position in IDEXX Laboratories by 4.6% in the 4th quarter. BlackRock Inc. now owns 6,549,022 shares of the company’s stock valued at $1,218,251,000 after buying an additional 289,208 shares in the last quarter. Geode Capital Management LLC increased its position in IDEXX Laboratories by 7.6% in the 4th quarter. Geode Capital Management LLC now owns 1,162,909 shares of the company’s stock valued at $215,959,000 after buying an additional 81,641 shares in the last quarter. Finally, Capital World Investors increased its position in IDEXX Laboratories by 0.3% in the 3rd quarter. Capital World Investors now owns 1,072,475 shares of the company’s stock valued at $267,754,000 after buying an additional 3,693 shares in the last quarter. 92.45% of the stock is currently owned by hedge funds and other institutional investors.
Shares of IDEXX Laboratories stock opened at $216.21 on Friday. IDEXX Laboratories, Inc. has a one year low of $176.11 and a one year high of $256.22. The stock has a market capitalization of $18.28 billion, a P/E ratio of 50.75 and a beta of 0.97.
A number of analysts recently commented on the company. Zacks Investment Research raised IDEXX Laboratories from a “hold” rating to a “strong-buy” rating and set a $236.00 target price for the company in a research report on Monday, February 4th. BidaskClub raised IDEXX Laboratories from a “sell” rating to a “hold” rating in a research report on Thursday, January 24th. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $246.00.
In other IDEXX Laboratories news, insider Giovani Twigge sold 1,500 shares of the business’s stock in a transaction that occurred on Thursday, February 28th. The stock was sold at an average price of $211.77, for a total transaction of $317,655.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Michael Lane sold 736 shares of the business’s stock in a transaction that occurred on Wednesday, February 20th. The stock was sold at an average price of $211.58, for a total value of $155,722.88. Following the sale, the vice president now directly owns 6,468 shares of the company’s stock, valued at $1,368,499.44. The disclosure for this sale can be found here. Insiders have sold a total of 40,144 shares of company stock valued at $8,378,892 over the last three months. Corporate insiders own 2.56% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This piece of content was published by Week Herald and is the property of of Week Herald. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States and international copyright law. The correct version of this piece of content can be read at https://weekherald.com/2019/03/17/legg-mason-asset-management-japan-co-ltd-sells-200-shares-of-idexx-laboratories-inc-idxx.html.
About IDEXX Laboratories
IDEXX Laboratories, Inc, together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments.
See Also: What is a back-end load?
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.